title: RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.
abstract: RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization.
authors.affiliation: Walter Reed National Military Medical Center, Murtha Cancer Center, Bethesda, Md., USA.
authors.forename: Corey A
authors.initials: CA
authors.lastname: Carter
authors.affiliation: EpicentRx Inc., Mountain View, Calif., USA.
authors.forename: Bryan T
authors.initials: BT
authors.lastname: Oronsky
authors.affiliation: EpicentRx Inc., Mountain View, Calif., USA.
authors.forename: Scott Z
authors.initials: SZ
authors.lastname: Caroen
authors.affiliation: EpicentRx Inc., Mountain View, Calif., USA.
authors.forename: Jan J
authors.initials: JJ
authors.lastname: Scicinski
authors.affiliation: Walter Reed National Military Medical Center, Murtha Cancer Center, Bethesda, Md., USA.
authors.forename: Aiste
authors.initials: A
authors.lastname: Degesys
authors.affiliation: Department of Radiation Oncology, University of Michigan, Ann Arbor, Mich., USA.
authors.forename: Michelle M
authors.initials: MM
authors.lastname: Kim
authors.affiliation: InterWest Partners, Menlo Park, Calif., USA.
authors.forename: Arnold L
authors.initials: AL
authors.lastname: Oronsky
authors.affiliation: Department of Physiology, University of Helsinki, Helsinki, Finland.
authors.forename: Harry
authors.initials: H
authors.lastname: Lybeck
authors.affiliation: Department of Bioengineering, University of California San Diego, La Jolla, Calif, USA.
authors.forename: Pedro
authors.initials: P
authors.lastname: Cabrales
authors.affiliation: CFLS Data, Mountain View, Calif., USA.
authors.forename: Neil
authors.initials: N
authors.lastname: Oronsky
authors.affiliation: Moores Cancer Center, University of California San Diego, La Jolla, Calif., USA.
authors.forename: Tony
authors.initials: T
authors.lastname: Reid
authors.affiliation: Walter Reed National Military Medical Center, Murtha Cancer Center, Bethesda, Md., USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Roswarski
authors.affiliation: Walter Reed National Military Medical Center, Murtha Cancer Center, Bethesda, Md., USA.
authors.forename: Christina
authors.initials: C
authors.lastname: Brzezniak
keywords: Epigenetic; Episensitization; Platinum doublets; Resensitization; Resistance; Small-cell lung cancer